Next Article in Journal
Impact of Glycosylation on Effector Functions of Therapeutic IgG
Next Article in Special Issue
Combinations of drugs in the Treatment of Obesity
Previous Article in Journal
Comparison of Functional Protein Transduction Domains Using the NEMO Binding Domain Peptide
Open AccessReview

Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options

Endocrine Department, Complejo Hospitalario Universitario A Coruña As Xubias 84, 15006 A Coruña, Spain
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(1), 125-145; https://doi.org/10.3390/ph3010125
Received: 8 November 2009 / Revised: 7 January 2010 / Accepted: 11 January 2010 / Published: 12 January 2010
(This article belongs to the Special Issue Anti-Obesity Drugs)
Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options. View Full-Text
Keywords: obesity; drug treatment; orlistat; sibutramine; rimonabant; leptin; ghrelin obesity; drug treatment; orlistat; sibutramine; rimonabant; leptin; ghrelin
Show Figures

Figure 1

MDPI and ACS Style

Isidro, M.L.; Cordido, F. Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options. Pharmaceuticals 2010, 3, 125-145.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop